NIPTE: A multi-university partnership supporting academic drug development

Drug Discovery Today

Volumn 18, Issue 19-20, 2013, Pages 916-921

  Gurvich, Vadim J ^a,b   Byrn, Stephen R ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b National Institute for Pharmaceutical Technology and Education   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; ORPHAN DRUG; PLACEBO; PROTEIN KINASE INHIBITOR;

ANALYTIC METHOD; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SYNTHESIS; EDUCATION; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; REVIEW; SCIENCE; TECHNOLOGY; TRAINING; TRANSLATIONAL RESEARCH; UNITED STATES; UNIVERSITY;

ACADEMIC MEDICAL CENTERS; ACADEMIES AND INSTITUTES; ANIMALS; DRUG DISCOVERY; HUMANS; TECHNOLOGY, PHARMACEUTICAL; TRANSLATIONAL MEDICAL RESEARCH; UNIVERSITIES;

EID: 84884591217     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.014     Document Type: Short Survey

References (34)

1. F. Pammolli The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
2. R. Kneller The importance of new companies for drug discovery: origins of a decade of new drugs Nat. Rev. Drug Discov. 9 2010 867 882
3. A.J. Stevens The role of public-sector research in the discovery of drugs and vaccines N. Engl. J. Med. 364 2011 535 541
4. W.L. Jorgensen Challenges for academic drug discovery Angew. Chem. Int. Ed. Engl. 51 2012 11680 11684
5. J. Frearson, and P. Wyatt Drug discovery in academia: the third way? Expert Opin. Drug Discov. 5 2010 909 919
6. D.P. Rotella Drug discovery 2012 and beyond ACS Med. Chem. Lett. 3 2012 172 173
7. D.M. Huryn Drug discovery in an academic setting: playing to the strengths ACS Med. Chem. Lett. 4 2013 313 315
8. A.A. Adjei Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent Clin. Cancer Res. 10 2004 4276S 4280S (Pubitemid 38812462)
9. R. Vince Acyclonucleosides to Ziagen: a journey Abstr. Pap. Am. Chem. Soc. 2011 242
10. G.D. Moore Fospropofol: a new sedative-hypnotic agent for monitored anesthesia care Ann. Pharmacother. 43 2009 1802 1808
11. J.H. Doroshow National Cancer Institute's Chemical Biology Consortium: an academic/public partnership for the discovery of novel cancer therapeutics Abstr. Pap. Am. Chem. Soc. 238 2009 368-ORGN
12. S. Frye US academic drug discovery Nat. Rev. Drug Discov. 10 2011 409 410
13. L.D. Coles, and J.C. Cloyd The role of academic institutions in the development of drugs for rare and neglected diseases Clin. Pharmacol. Ther. 92 2012 193 202
14. A. Philippidis Academia increasingly going beyond basic research by setting up translational med centers Genet. Eng. Biotechnol. News 30 May 2012
15. R.F. Service New institute aims to help academics make medicines Science 335 2012 1288 1289 erratum 336, 541
16. I. Khanna Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discov. Today 17 2012 1088 1102
17. L.M. Portilla Advancing translational research collaborations Sci. Transl. Med. 2 2010 63cm30
18. R.J. Williams Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective Drug Discov. Today 17 2012 185 187
19. A. Mullard European lead factory opens for business Nat. Rev. Drug Discov. 12 2013 173 175
20. A.P. Kozikowski Why academic drug discovery makes sense Science 313 2006 1235 1236 (Pubitemid 44330930)
21. D. Butler Translational research: crossing the valley of death Nature 453 2008 840 842 (Pubitemid 351832542)
22. B.S. Coller, and R.M. Califf Traversing the valley of death: a guide to assessing prospects for translational success Sci. Transl. Med. 1 2009 10cm9
23. D.J. Adams The valley of death in anticancer drug development: a reassessment Trends Pharmacol. Sci. 33 2012 173 180
24. M. Palucki Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates J. Med. Chem. 53 2010 5897 5905
25. J.O. Henck, and S.R. Byrn Designing a molecular delivery system within a preclinical timeframe Drug Discov. Today 12 2007 189 199
26. S.R. Byrn Accelerating proof of concept for small molecule drugs using solid-state chemistry J. Pharm. Sci. 99 2010 3665 3675
27. N.A. Meanwell The emerging utility of co-crystals in drug discovery and development J.E. Macor, Annual Reports in Medicinal Chemistry vol. 43 2008 Elsevier Academic Press, Inc 373 404
28. R. Chugh Minnelide: a novel therapeutic strategy against pancreatic cancer Pancreas 38 2009 989
29. R. Chugh Minnelide: single chemotherapeutic agent against pancreatic cancer Pancreas 39 2010 1314 1315
30. R. Chugh A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer Sci. Transl. Med. 4 2012 156ra139
31. S.R. Hingorani, and J.D. Potter Pancreas cancer meets the thunder god Sci. Transl. Med. 4 2012 156ps21
32. S. Svenson Dendrimers as versatile platform in drug delivery applications Eur. J. Pharm. Biopharm. 71 2009 445 462
33. R. Longman Lilly's chorus experiment In Vivo: Bus. Med. Rep. 25 2007 1 5
34. D. Engers A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion J. Pharm. Sci. 99 2010 3901 3922